

## BIBLIOGRAFIA

1. **Mortalidad por cáncer y otras causas en España, año 2000. Centro Nacional de Epidemiología, 2000. En: <http://193.146.50.130/cancer/cancer1.htm>.**
2. **Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, 10.<sup>a</sup> ed. Lyon: IARC Press, 2001.**
3. **Viñes JJ, Ardanaz E, Aráosla A, Gaminde I Epidemiología poblacional de cáncer colorrectal: revisión de la causalidad. An Sist San Navarra 2003; 26(19):79-97**
4. **Bowles CJA, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut 2004;53:277-83.**
5. **Levin TR, Farraye FA, Schoen RE, Hoff G, Atkin W, Bond JH, Winawer S, Burt RW, Johnson DA, Kirk LM, Litin SC, Rex DK. Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut. 2005 Jun;54(6):807-13**
6. **Características de los indicadores clínicos. Joint Commission on Accreditation of Healthcare Organizations. Control de Calidad Asistencial,1991;6,3:65-74**

7. Rex DK, Petrini JL, Baron TH, Chak A, Cohen J, Deal SE, Hoffman B, Jacobson BC, Mergener K, Petersen BT, Safdi MA, Faigel DO, Pike IM. Quality indicators for colonoscopy. *Gastrointest Endosc.* 2006 Apr;63(4 Suppl):S16-28
8. Rex DK, Bond JH, Winawer S, Levin TR, Burt RW, Johnson DA, et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on colorectal cancer. *Am J Gastroenterol* 2002;97:1296-308.
9. Lieberman D. Quality and colonoscopy: a new imperative. *Gastrointest Endosc.* 2005 Mar;61(3):392-4.
10. Faigel DO, Pike IM, Baron TH, Chak A, Cohen J, Deal SE, Hoffman B, Jacobson BC, Mergener K, Petersen BT, Petrini JL, Rex DK, Safdi MA; ASGE/ACG Taskforce on Quality in Endoscopy. Quality indicators for gastrointestinal endoscopic procedures: an introduction. *Am J Gastroenterol.* 2006 Apr;101(4):866-72
11. Atkin W, Rogers P, Cardwell C, et al. Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. *Gastroenterology* 2004;126:1247–1256
12. Schoen RE, Pinsky PF, Weissfeld JL, et al. Results of repeat sigmoidoscopy 3 years after a negative examination. *JAMA* 2003;290:41–48

13. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. *Gastroenterology* 1997;112:24–28.
14. Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of adenomas missed by optical colonoscopy. *Ann Intern Med* 2004;141:352–359.
15. Bressler B, Paszat LF, Vinden C, et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. *Gastroenterology* 2004;127:452–456 (PJ, 2000)
16. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study *N Engl J Med.* 1993;328:1365–71.
17. Steinitz R, Parkin DM, Young JL, Bieber CA, Katz L. Cancer incidence in Jewish migrants to Israel, 1961-1981. *IARC Sci Publ.* 1989;(98):1-311.)
18. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Results of screening colonoscopy among persons 40 to 49 years of age. *N Engl J Med.* 2002 Jun 6;346(23):1781-5.
19. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. *J Natl Cancer Inst.* 1994 Jul 6;86(13):997-1006.

20. Broders AC, The grading of Carcinoma. *Minnesota Med* 1925;8,726
  
21. Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Hakulinen T, Micheli A et al. Toward a comparison of survival in American and European cancer patients. *Cancer* 2000; 89: 893-900.
  
22. . Ahlquist DA, Pasha TM. Clinical aspects of sporadic colorectal cancer. En: Rustgi AK, ed. *Gastrointestinal cancers*. Filadelfia: Saunders, 2003; 379-405
  
23. MutoT, BusseyHJR, MorsonBC. The evolution of cancer of the colon and rectum. *Cancer* 1975;36:2251-70.
  
24. FearonER, VogelsteinB. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759-67.
  
25. Chung DC. The genetic basis of colorectal cancer insights into critical pathways of tumorigenesis. *Gastroenterology* 2000;119:854-65.
  
26. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy .*N Engl J Med* 1993;329:1977-81.

27. Castells A, Marzo M, Bellas B, Amador FJ, Lanás A, Mascort JJ, Ferrándiz J, Alonso P, Piñol V, Fernández M, Bonfill X, Piqué JM. Clinical guidelines for the prevention of colorectal cancer. *Gastroenterol Hepatol*. 2004 Dec;27(10):573-634
28. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colo-rectal cancer. *N Engl J Med* 2000;343:1603-7.
29. Piñol V, Andreu M, Castells A, Payá A, Bessa X, Rodrigo J; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. *Eur J Gastroenterol Hepatol*. 2004 Jan;16(1):39-45.
30. Alonso A, Moreno S, Valiente A, Artigas A, Pérez-Juana A, Ramos-Arroyo MA., Genetic mechanisms in the hereditary predisposition to colorectal cancer *An. Sist. Sanit. Navar*. 2006; 29 (1): 59-76.
31. Balaguer F, Castellví-Bel S, Castells A, Andreu M, Muñoz J, Gisbert JP, Llor X, Jover R, de Cid R, Gonzalo V, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Piqué JM; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol*. 2007 Mar;5(3):379-87

32. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; 48: 526-535.
33. Ullman TA. Dysplasia and colorectal cancer in Crohn's disease. *J Clin Gastroenterol* 2003; 36: S75-S78.
34. Giovannucci E. Modifiable risk factors for colon cancer. *Gastroenterol Clin North Am* 2002; 31: 925-943
35. Giovannucci E, Goldin B. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. *Am J Clin Nutr* 1997; 66: 1.564S-1.571S.
36. Sandhu MS, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 439-446.
37. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: an estimate of attributable and preventable fractions. *IARC Sci Publ* 2002; 156: 223-225
38. Burkitt DP. Fibre-depleted carbohydrates and disease *Community Health (Bristol)*. 1975 Jan-Feb;6(4):190-4.

39. **Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003; 78: 559S-569S.**
  
40. **Peters U, Sinha R, Chatterjee N, Subar AF, Ziegler RG, Kulldorff M et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003; 361: 1.491-1.495.**
  
41. **Norat T, Riboli E. Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr 2003; 57: 1-17.**
  
42. **IARC Working Group on the Evaluation of Cancer-Preventive Agents. Weight control and physical activity. Handbooks of cancer prevention, vol. 6. Lyon: IARC Press, 2002.**
  
43. **Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A metaanalysis of alcohol drinking and cancer risk. Br J Cancer 2001; Nov 30;85(11):1700-5.**
  
44. **Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 725-731.**
  
45. **Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002; 252: 206-224**

46. **Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. *Cancer Epidemiol Biomarkers Prev* 1998; 7: 653-659.**
  
47. **Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. *N Engl J Med* 1999; 340: 101-107.**
  
48. **Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. *J Natl Cancer Inst* 1999; 91: 2.102-2.106.**
  
49. **Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). *Cancer Causes Control* 2000; 11: 617-626.**
  
50. **Baron JA, Cole BF, Mott L, Haile R, Grau M, Church TR et al. Neoplastic and Antineoplastic Effects of beta-Carotene on Colorectal Adenoma Recurrence: Results of a Randomized Trial. *J Natl Cancer Inst* 2003; 95: 717-722.**
  
51. **Ritenbaugh C, Streit K, Helfand M. Routine supplementation to prevent cancer: a summary of the evidence from randomized controlled trials for the U.S. Preventive Task Force. En: <http://www.ahcpr.gov/clinic/3rduspstf/vitamins/vitasum.htm>**



52. **Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-720.**
53. **Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1.220-1.224.**
54. **Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65 (4): 281-393**
55. **Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW et al. Randomised controlled trial of fae-cal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1.472-1.477.**
56. **Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colo-rectal cancer: results from a randomised controlled trial. Gut 2002; 50: 840-844.**
57. **Towler B, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemocult. Cochrane Database Systematic Review 2000;**

58. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996; 348: 1.467-1.471.
59. Scholefield JH, Moss SM. Faecal occult blood screening for colorectal cancer. *J Med Screen* 2002; 9: 54-55.
60. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2002; 137: 132-141.
61. Young GP, St John DJ, Winawer SJ, Rozen P; WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy). Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. *Am J Gastroenterol.* 2002 Oct;97(10):2499-507
62. Cole SR, Young GP. Participation in faecal occult blood test-based screening for colorectal cancer is reduced by dietary restriction. *Med J Aust* 2001;175:195–8.
63. Herbert C, Launoy G, Thezee Y, Maurel J, Richir B, Reaud JM, Ollivier V, Pegulu L, Valla A, Gignoux M. Participants' characteristics in a French colorectal cancer mass screening campaign. *Prev Med.* 1995 Sep;24(5):498-502.

64. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. *Lancet* 2002;359:1291–1300.
65. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"—SCORE. *J Natl Cancer Inst* 2002;94:1763–1772.
66. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50–64 years. *Scand J Gastroenterol* 2003;38:635–642.
67. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. *J Natl Cancer Inst* 2005;97:989–997
68. Imperiale TF, Wagner DR, Lin CY, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. *N Engl J Med* 2000;343:169–174.

69. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. *N Engl J Med* 2001;345:555–560
70. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. *N Engl J Med* 2000;343:162–168
71. Schoenfeld P, Lipscomb S, Crook J, Dominguez J, Butler J, Holmes L et al. Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial. *Gastroenterology* 1999; 117: 312-318.
72. Gross CP, Andersen MS, Krumholz HM, et al. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. *JAMA* 2006;296:2815–2822
73. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Wayne JD et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. *N Engl J Med* 2000; 342: 1.766-1.772.

74. Schroy PC, 3rd, Lal S, Glick JT, et al. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? *Am J Manag Care* 2007;13:393–400
75. Zubarik R, Ganguly E, Benway D, et al. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. *Am J Gastroenterol* 2002;97:3056–3061
76. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. *Arch Intern Med* 1995; 155: 1.741-1.748
77. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effective-ness of screening for colorectal cancer in the general population. *JAMA* 2000; 284: 1.954-1.961.
78. Rex DK, Cummings OW, Helper DJ, Nowak TV, McGill JM, Chiao GZ et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons. *Gastroenterology* 1996; 111: 1.178-1.181.
79. Winawer SJ, Zauber AG, Church T, Mandelson M, Feld A, Bond J et al. National Colonoscopy Study (NCS) preliminary results: a randomized controlled trial of general population screening colonoscopy. *Gastroenterology* 2002; 122: A480 [abstract].

80. Heresbach D, Barrioz T, Lapalus MG, Coumaros D, Bauret P, Potier P, Sautereau D, Boustière C, Grimaud JC, Barthélémy C, Sée J, Serraj I, D'Halluin PN, Branger B, Ponchon T. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. *Endoscopy*. 2008 Apr;40(4):333-5.
81. Haseman JH, Lemmel GT, Rahmani EY, Rex DK. Failure of colonoscopy to detect colorectal cancer: evaluation of 47 cases in 20 hospitals. *Gastrointest Endosc* 1997; 45: 451-455
82. Rembacken BJ, Fujii T, Cairns A, Dixon MF, Yoshida S, Chalmers DM et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. *Lancet* 2000; 355: 1.211-1.214.
83. Brooker JC, Saunders BP, Shah SG, Thapar CJ, Thomas HJ, Atkin WS et al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. *Gastrointest Endosc* 2002; 56: 333-338
84. Gatto NM, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. *J Natl Cancer Inst* 2003;95:230–236
85. Macafee DA, Scholefield JH. Antagonist: population based endoscopic screening for colorectal cancer. *Gut* 2003; 52: 323326

86. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. *JAMA*. 2006 May 24;295(20):2366-73.
  
87. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. *N Engl J Med* 2000;342:1156–1162
  
88. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. *N Engl J Med* 2000;342:1149–1155
  
89. Bressler B, Paszat LF, Vinden C, et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. *Gastroenterology* 2004;127:452–456
  
90. Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. *Ann Intern Med* 2004;141:264–271
  
91. Lefere P, Gryspeerdt S, Marrannes J, et al. CT colonography after fecal tagging with a reduced cathartic cleansing and a reduced volume of barium. *AJR Am J Roentgenol* 2005;184:1836–1842

92. Iannaccone R, Laghi A, Catalano C, et al. Computed tomographic colonography without cathartic preparation for the detection of colorectal polyps. *Gastroenterology* 2004;127:1300–1311
93. Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA* 2004;291:1713–1719
94. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. *Lancet* 2005;365:305–311
95. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N Engl J Med* 2003;349:2191–2200.
96. Halligan S, Altman DG, Taylor SA, et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. *Radiology* 2005;237:893–904.
97. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. *Ann Intern Med* 2005;142:635–650.



98. **Syngal S, Stoffel E, Chung D, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. *Cancer* 2006;106:277–283**
99. **Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. *Clin Gastroenterol Hepatol* 2007;5:111–117**
100. **Schroy PC, 3rd, Lal S, Glick JT, et al. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? *Am J Manag Care* 2007;**
101. **Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. *Ann Intern Med* 2002;137:96–104**
102. **Propuesta de Recomendación del Consejo sobre cribado del cáncer. Comisión de las Comunidades Europeas, 2003. En: <http://www.who.int/cancer/nccp/en/ecproposalforcouncilre-commendationes.pdf>**
103. **Eddy DM. Screening for colorectal cáncer. *Ann Intern Med.* 1990;1-3.373-84.**
104. **Rich JS, Black WC. When should we stop screening? *Eff Clin Pract.* 2000; 3:78-84.**

105. **Gómez-Domínguez E, Trapero-Marugán M, del Pozo AJ, Cantero J, Gisbert JP, Maté J . The colorectal carcinoma prognosis factors. Significance of diagnosis delay.Rev Esp Enferm Dig. 2006 May;98(5):322-9.**
  
106. **Walsh JM, Posner SF, Perez-Stable EJ. Colon cancer screening in the ambulatory setting. Prev Med. 2002 Sep;35(3):209-18**
  
107. **Greisinger A, Hawley ST, Bettencourt JL, Perz CA, Vernon SW. Primary care patients' understanding of colorectal cancer screening. Cancer Detect Prev. 2006;30(1):67-74. Epub 2006 Feb 2.**
  
108. **Stone EG, Morton SC, Hulscher ME, Maglione MA, Roth EA, Grimshaw JM et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med 2002; 136: 641-651.**
  
109. **Plan Integral del Cáncer. Detección precoz. Dirección General Agencia de Calidad, 2003.**
  
110. **Plan de Salud 2003-2007.Región de Murcia.Consejería de Sanidad de la Comunidad Autónoma de la Región de Murcia.2003**

111. Aguiar R, Gimeno AZ, Parra A, Nicolas D, Garcia M, Déniz D, Serrano P, Hernández A, León F, Eishi Y, Sano Y, Quintero E. Coste-efectividad del test inmunológico de sangre oculta en heces para el cribado del Cáncer Colorectal en población de riesgo intermedio. Congreso de la AEG 2004. Abstract
  
112. Rodríguez- Moranta. Requerimientos endoscópicos de un programa de cribado poblacional del cáncer colorrectal (CCR) en España. Simulación en base a un modelo de Markov. Congreso de la AEG, 2005. Abstract
  
113. Rodríguez-Moranta F, Trapero-Bertran M, Castells A, Mas-Canal X, Balaguer F, Pellise M, Gonzalo V, Ocaña T, Trillab A, Pique JM. Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model. Gastroenterol Hepatol. 2008;31(7):405-12
  
114. Brown ML, Klabunde CN, Mysliwiec P. Current capacity for endoscopic colorectal cancer screening in the United States: data from the National Cancer Institute survey of colorectal cancer screening practices. Am J Med 2003; 115: 129-33.
  
115. S. Vijan; J. Inadomi; R. A. Hayward; T. P. Hofer; A. M. Fendrick. Projections of Demand and Capacity for Colonoscopy Related to Increasing Rates of Colorectal Cancer Screening in the United States. Aliment Pharmacol Ther 20(5):507-515, 2004.

116. Saturno PJ, Quintana O, Varo J. ¿Qué es calidad? En: Tratado de Calidad Asistencial en Atención Primaria. Madrid :Dupont Pharma;1997. P 17-45
117. Juran JM. La función de calidad. En: Juran JM, Gryma FM. Manual de Control de Calidad. Volumen I. Madrid: McGraw-Hill;1993. P. 2.1-2.13
118. Ishikawa K. La esencia del control de calidad. En: Ishikawa K.¿Qué es control de total de calidad? Madrid: Parramón;1994 p. 61-90
119. Deming WE. Calidad, productividad y competitividad. La salida de la crisis. Madrid: Diaz de Santos; 1989
120. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal HS. Prospective study of the frequency and size distributions of polyps missed by colonoscopy. J Natl Cancer Inst 1990;82:1769-72.
121. Pabby A, Schoen RE, Weissfeld JL, Burt R, Kikendall JW, Lance P, et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005;61:385-91.

122. Kim KC, Friedland S, Rouse RV, Kosek J, Matsui SM, Soetikno RM. Clinical importance of flat and depressed lesions in American veterans with in situ and submucosally invasive colorectal adenocarcinoma [abstract]. *Gastrointest Endosc* 2004;59:AB110
123. Lieberman D, Nadel M, Smith RA, Atkin W, Duggirala SB, Fletcher R, Glick SN, Johnson CD, Levin TR, Pope JB, Potter MB, Ransohoff D, Rex D, Schoen R, Schroy P, Winawer S. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest Endosc*. 2007 May;65(6):757-66.
124. Williams C. Insertion technique. In: Waye J, Rex D, Williams C, editors. *Colonoscopy: principles and practice*. Oxford: Blackwell Publishing;2003. p. 318-38.
125. Barclay R, Vicari JJ, Johanson JF, et al. Variation in adenoma detection rates and colonoscopic withdrawal times during screening colonoscopy [abstract]. *Gastrointest Endosc* 2005;61:AB107
126. Rex DK. Colonoscopic withdrawal technique is associated with adenoma miss rates. *Gastrointest Endosc* 2001;51:33-6.
127. Ware JE Jr, Snyder MK, Wright WR, Davies AR. Defining and measuring patient satisfaction with medical care. *Eval Program Plann*. 1983;6(3-4):247-63.

128. Larsen IK, Grotmol T, Bretthauer M, Gondal G, Huppertz-Hauss G, Hofstad B, Efskind P, Jørgensen A, Hoff G. Continuous evaluation of patient satisfaction in endoscopy centres. *Scand J Gastroenterol.* 2002 Jul;37(7):850-5.
129. Sanchez del Rio A, Alarcon Fernandez O, Baudet JS, Sainz Menendez Z, Socas Mendez M. Reliability of the Spanish version of a brief questionnaire on patient satisfaction with gastrointestinal endoscopy. *Rev Esp Enferm Dig.* 2005 Aug;97(8):554-61.
130. Johanson JF. Continuous quality improvement in the ambulatory endoscopy center. *Gastrointest Endosc Clin N Am* 2002; 12: 351-66.
131. Rex DK; ACG Board of Trustees. American College of Gastroenterology action plan for colorectal cancer prevention. *Am J Gastroenterol.* 2004 Apr;99(4):574-7.
132. Marshall JB, Barthel JS. The frequency of total colonoscopy and terminal ileal intubation in the 1990s. *Gastrointest Endosc* 1993;39:518-20.
133. Rex DK. Still photography versus videotaping for documentation of cecal intubation: a prospective study. *Gastrointest Endosc* 2000;51:451-9
134. Rex DK. Quality in colonoscopy: cecal intubation first, then what? *Am J Gastroenterol.* 2006 Apr;101(4):732-4.

135. Marshall JB, Barthel JS. The frequency of total colonoscopy and terminal ileal intubation in the 1990s. *Gastrointest Endosc* 1993;39:518-20
136. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. *Gastroenterology*. 2003 Feb;124(2):544-60.
137. Citarda F, Tomaselli G, Capocaccia R, et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. *Gut* 2001;48:812-5.
138. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. *Gut*. 2002 Jan;50(1):29-32.
139. Simmons DT, Harewood GC, Baron TH, Petersen BT, Wang KK, Boyd-Enders F, Ott BJ. Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time. *Aliment Pharmacol Ther*. 2006 Sep 15;24(6):965-71
140. ASGE. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. *Gastrointest Endosc* 1998;48:672-5.

141. ASGE. Antibiotic prophylaxis for gastrointestinal endoscopy. *Gastrointest Endosc* 1995;42:630–5.
142. Rex DK, Khalfan HK. Sedation and the technical performance of colonoscopy. *Gastrointest Endosc Clin N Am*. 2005 Oct;15(4):661-72
143. Practice guidelines for sedation and analgesia by non-anesthesiologists. An updated report by the American Society of Anesthesiologists Task Force on sedation and analgesia by non-anesthesiologists. *Anesthesiology* 2002; 96: 1004–17.
144. Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications: results of the 1974 American Society for Gastrointestinal Endoscopy Survey. *JAMA* 1976;235:928-30.
145. Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. *Am J Gastroenterol* 2000;95: 3418-22.
146. Rex DK, Lewis BS, Waye JD. Colonoscopy and endoscopic therapy for delayed post-polypectomy hemorrhage. *Gastrointest Endosc* 1992; 38:127-9
147. Johnson DA, Gurney MS, Volpe RJ, et al. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. *Am J Gastroenterol* 1990;85:969–74.



148. Chen SC, Rex DK. Endoscopist can be more powerful than age and male gender in predicting adenoma detection at colonoscopy. *Am J Gastroenterol.* 2007 Apr;102(4):862-3